Form 4: Exact Sciences Director Sells Shares Post-Abbott Merger

Exact Sciences Director Katherine S. Zanotti reported the disposal of all her common stock holdings following the company's acquisition by Abbott Laboratories for $105.00 per share in cash.

Summary

• Katherine S. Zanotti, a Director of Exact Sciences Corporation, reported changes in beneficial ownership.
• The changes occurred on March 23, 2026, following the merger of Exact Sciences with Badger Merger Sub I, Inc., a direct, wholly-owned subsidiary of Abbott Laboratories.
• Exact Sciences is now a direct, wholly-owned subsidiary of Abbott Laboratories.
• Each share of Exact Sciences common stock, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest.
• Shares of common stock subject to vesting, repurchase, or other lapse restriction were deemed fully vested, cancelled, and converted into the right to receive the $105.00 cash merger consideration, less any applicable tax withholding.
• Ms. Zanotti disposed of 55,361 shares of Common Stock and an additional 5,398 shares of Common Stock on March 23, 2026, totaling 60,759 shares.
• Following these reported transactions, Ms. Zanotti beneficially owns 0 shares of Exact Sciences common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for Exact Sciences shareholders who received a cash payout, but it marks the end of Exact Sciences as an independent public company, which could be seen as neutral for the broader market.

Positives

• Shareholders of Exact Sciences received a cash consideration of $105.00 per share, indicating a successful acquisition for existing shareholders.
• Vested stock awards were converted to cash, providing liquidity to employees/directors holding such awards.

Negatives

• Exact Sciences Corporation ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Abbott Laboratories.

Future Outlook

The filing indicates the completion of the merger, with Exact Sciences becoming a wholly-owned subsidiary of Abbott Laboratories. This implies that Exact Sciences' future operations and financial reporting will be integrated into Abbott Laboratories, and it will no longer operate as an independent public entity.

Industry Context

StockSavvy.ai notes that this merger signifies a consolidation within the diagnostics and healthcare technology sector, with a larger player like Abbott Laboratories integrating Exact Sciences' innovative diagnostic capabilities, particularly in cancer screening. This trend reflects a broader industry movement towards expanding product portfolios and market reach through strategic acquisitions.

Comparison to Industry Standards

• StockSavvy.ai observes that the cash consideration of $105.00 per share for Exact Sciences common stock is a specific valuation tied to the merger agreement. Without the full merger agreement details or market data at the time of the agreement, a direct comparison to other specific diagnostic company acquisitions (e.g., Roche's acquisition of GenMark Diagnostics, Siemens Healthineers' acquisition of Varian Medical Systems) is not fully detailed in this Form 4. However, such transactions typically involve a premium over pre-announcement trading prices, reflecting strategic value and synergies.

Stakeholder Impact

• Shareholders: Received $105.00 cash per share, providing a definitive return on investment.
• Employees (with stock awards): Vested stock awards converted to cash, providing liquidity.
• Company (Exact Sciences): Ceased to be an independent public entity, now integrated into Abbott Laboratories.

Next Steps

• Integration of Exact Sciences' operations and assets into Abbott Laboratories.
• Exact Sciences will continue to operate as a wholly-owned subsidiary of Abbott Laboratories.

Key Dates

Keywords

Exact Sciences, EXAS, Abbott Laboratories, Merger, Acquisition, Form 4, Insider Transaction, Stock Disposal, Cash Consideration